Impact of Fecal Microbiota Transplantation on Gut Bacterial Bile Acid Metabolism in Humans
Authors:
- Jessica-Miranda BustamanteJBJessica-Miranda Bustamante
- Tyson DawsonTyson Dawson
- Caitlin LoefflerCLCaitlin Loeffler
- Zara MarforiZMZara Marfori
- Julian R. MarchesiJMJulian R. Marchesi
- Benjamin H. MullishBMBenjamin H. Mullish
- Christopher C. ThompsonCTChristopher C. Thompson
- Keith A. CrandallKeith A. Crandall
- Ali RahnavardARAli Rahnavard
- Jessica R. AllegrettiJAJessica R. Allegretti
- Bethany P. CummingsBCBethany P. Cummings
Open Access
Abstract
Fecal microbiota transplantation (FMT) is a promising therapeutic modality for the treatment and prevention of metabolic disease. We previously conducted a double-blind, randomized, placebo-controlled pilot trial of FMT in obese metabolically healthy patients in which we found that FMT enhanced gut bacterial bile acid metabolism and delayed the development of impaired glucose tolerance relative to the placebo control group. Therefore, we conducted a secondary analysis of fecal samples collected from these patients to assess the potential gut microbial species contributing to the effect of FMT to improve metabolic health and increase gut bacterial bile acid metabolism. Fecal samples collected at baseline and after 4 weeks of FMT or placebo treatment underwent shotgun metagenomic analysis. Ultra-high-performance liquid chromatography-mass spectrometry was used to profile fecal bile acids. FMT-enriched bacteria that have been implicated in gut bile acid metabolism included Desulfovibrio fairfieldensis and Clostridium hylemonae. To identify candidate bacteria involved in gut microbial bile acid metabolism, we assessed correlations between bacterial species abundance and bile acid profile, with a focus on bile acid products of gut bacterial metabolism. Bacteroides ovatus and Phocaeicola dorei were positively correlated with unconjugated bile acids. Bifidobacterium adolescentis, Collinsella aerofaciens, and Faecalibacterium prausnitzii were positively correlated with secondary bile acids. Together, these data identify several candidate bacteria that may contribute to the metabolic benefits of FMT and gut bacterial bile acid metabolism that requires further functional validation.Keywords
Funding Information
- National Institutes of Health (R21AT010956, MC_PC_12025)
- Medical Research Council (MRC) (R21AT010956, MC_PC_12025)
- NIHR Imperial Biomedical Research Centre (BRC) (R21AT010956, MC_PC_12025)
This publication has 37 references indexed in Scilit:
- Gut metagenome in European women with normal, impaired and diabetic glucose controlNature, 2013
- A core gut microbiome in obese and lean twinsNature, 2008
- Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiomeProceedings of the National Academy of Sciences, 2008
- Diet-Induced Obesity Is Linked to Marked but Reversible Alterations in the Mouse Distal Gut MicrobiomeCell Host & Microbe, 2008
- Desulfovibrio fairfieldensis Bacteremia Associated with Choledocholithiasis and Endoscopic Retrograde CholangiopancreatographyJournal of Clinical Microbiology, 2007
- Human gut microbes associated with obesityNature, 2006
- An obesity-associated gut microbiome with increased capacity for energy harvestNature, 2006
- Cloning and characterization of a bile salt hydrolase (bsh) from Bifidobacterium adolescentisBiotechnology Letters, 2005
- Identification of membrane-type receptor for bile acids (M-BAR)Biochemical and Biophysical Research Communications, 2002
- Assignment of Eubacterium sp. VPI 12708 and related strains with high bile acid 7alpha-dehydroxylating activity to Clostridium scindens and proposal of Clostridium hylemonae sp. nov., isolated from human faeces.International Journal of Systematic and Evolutionary Microbiology, 2000